bisoprolol aurovitas 10 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - bisoprololi fumaras - tabletki powlekane - 10 mg
betaxolol pmcs 20 mg tabletki
pro.med.cs praha a.s. - betaxololi hydrochloridum - tabletki - 20 mg
betaxomyl 20 mg tabletki powlekane
mylan ireland limited - betaxololi hydrochloridum - tabletki powlekane - 20 mg
acebutolol aurovitas 200 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - acebutololi hydrochloridum - tabletki powlekane - 200 mg
acebutolol aurovitas 400 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - acebutololi hydrochloridum - tabletki powlekane - 400 mg
propranolol aurovitas 10 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - propranolol hydrochloride - tabletki powlekane - 10 mg
propranolol aurovitas 40 mg tabletki powlekane
aurovitas pharma polska sp. z o.o. - propranolol hydrochloride - tabletki powlekane - 40 mg
aubagio
sanofi winthrop industrie - teriflunomide - stwardnienie rozsiane - selektywne leki immunosupresyjne - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
fampyra
biogen netherlands b.v. - fampridine - stwardnienie rozsiane - inne leki na układ nerwowy - produkt leczniczy fampyra jest wskazany w leczeniu chodzenia u dorosłych pacjentów ze stwardnieniem rozsianym, z chodzeniem niepełnosprawności (rozszerzona skala 4-7).
tysabri
biogen netherlands b.v. - natalizumab - stwardnienie rozsiane - selektywne leki immunosupresyjne - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 i 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.